Axsome Therapeutics Management
Management criteria checks 2/4
Axsome Therapeutics' CEO is Herriot Tabuteau, appointed in Jan 2012, has a tenure of 12.33 years. total yearly compensation is $9.90M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth $541.34K. The average tenure of the management team and the board of directors is 4.9 years and 9.4 years respectively.
Key information
Herriot Tabuteau
Chief executive officer
US$9.9m
Total compensation
| CEO salary percentage | 7.6% |
| CEO tenure | 12.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 4.9yrs |
| Board average tenure | 9.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$10m | US$750k | -US$239m |
| Sep 30 2023 | n/a | n/a | -US$202m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$8m | US$685k | -US$187m |
| Sep 30 2022 | n/a | n/a | -US$160m |
| Jun 30 2022 | n/a | n/a | -US$150m |
| Mar 31 2022 | n/a | n/a | -US$141m |
| Dec 31 2021 | US$8m | US$685k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$126m |
| Jun 30 2021 | n/a | n/a | -US$114m |
| Mar 31 2021 | n/a | n/a | -US$100m |
| Dec 31 2020 | US$7m | US$575k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$95m |
| Mar 31 2020 | n/a | n/a | -US$90m |
| Dec 31 2019 | US$5m | US$435k | -US$68m |
| Sep 30 2019 | n/a | n/a | -US$53m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$1m | US$435k | -US$31m |
| Sep 30 2018 | n/a | n/a | -US$29m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$1m | US$435k | -US$29m |
Compensation vs Market: Herriot's total compensation ($USD9.90M) is above average for companies of similar size in the UK market ($USD2.59M).
Compensation vs Earnings: Herriot's compensation has increased whilst the company is unprofitable.
CEO
Herriot Tabuteau (55 yo)
12.3yrs
Tenure
US$9,896,629
Compensation
Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.3yrs | US$9.90m | 0.015% $ 541.3k | |
| Chief Financial Officer | 6yrs | US$3.57m | 0.089% $ 3.2m | |
| Chief Operating Officer | 8.6yrs | US$4.04m | 0% $ 0 | |
| General Counsel & Secretary | 2.4yrs | US$3.06m | 0% $ 0 | |
| Executive Vice President of Product Strategy | 3.8yrs | no data | no data | |
| Executive VP & Head of Commercial | less than a year | no data | no data |
4.9yrs
Average Tenure
45yo
Average Age
Experienced Management: 0HKF's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.3yrs | US$9.90m | 0.015% $ 541.3k | |
| Independent Lead Director | 9.4yrs | US$400.34k | 0.35% $ 12.6m | |
| Independent Director | 9.4yrs | US$405.34k | 0.022% $ 771.5k | |
| Independent Director | less than a year | US$417.48k | no data | |
| Independent Director | 9.4yrs | US$427.84k | 0.90% $ 32.1m |
9.4yrs
Average Tenure
55yo
Average Age
Experienced Board: 0HKF's board of directors are considered experienced (9.4 years average tenure).